Search clinical trials for: Standard chemotherapy CHOP Ritiximab

Total 481 results

Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Ruijin Hospital

Active, not recruiting

Reduced Chemotherapy in Low Risk DLBCL

Diffuse Large B-cell Lymphoma

China
Fondazione Italiana Linfomi ONLUS

Unknown

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
The Lymphoma Academic Research Organisation

Terminated

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

DLBCL

Belgium, France
Lymphoma Study Association
Hoffmann-La Roche

Completed

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Untreated T-cell Angioimmunoblastic Lymphoma

France
Peking University People's Hospital

Recruiting

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

HER2-negative Early Breast Cancer

China
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Assisi Foundation

Completed

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Leukemia, Myeloid, Acute | Myelodysplastic Syndrome | T-cell Lymphoblastic Lymphoma | Leukemia, Lymphocytic, Acute, T-Cell | Juvenile Myelomonocytic Leukemia Lymphoblastic

United States
Genentech, Inc.

Completed

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) (RATE)

Non-Hodgkin's Lymphoma
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

EBV-Positive DLBCL, Nos

China
Celgene

Completed

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Diffuse B-Cell Lymphoma

Canada, Spain, Belgium, United States
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL (ANZINTER3)

Diffuse Large B Cell Lymphoma (DLBCL) | Elderly Patients (>65 Years)

Italy
Trans Tasman Radiation Oncology Group
Australasian Leukaemia and Lymphoma Group

Completed

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Follicular Lymphoma

Australia, New Zealand, Canada
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
University of Southern California
Ortho Biotech, Inc.

Completed

Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...
Janssen-Cilag, S.A.

Completed

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Diffuse, Large B-Cell, Lymphoma

Spain
Hebei Medical University Fourth Hospital

Unknown

The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

United States
National Cancer Institute (NCI)

Terminated

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
Cancer Research UK

Unknown

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Lymphoma

United Kingdom
Tehran University of Medical Sciences

Unknown

Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

Osteopetrosis

Iran, Islamic Republic of
Asan Medical Center
Korean Breast Cancer Study Group

Unknown

Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (NEST)

Breast Cancer

Korea, Republic of
Polish Lymphoma Research Group

Completed

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (PLRG4)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

Poland
University College, London
Pfizer; Cancer Research UK

Completed

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (INCA)

Diffuse Large B Cell Lymphoma

United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Peking Union Medical College Hospital

Recruiting

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Intravascular Large B-Cell Lymphoma

China
Northwestern University

Terminated

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

MYOPATHY

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
Samsung Medical Center

Completed

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Korea, Republic of
Hoffmann-La Roche
Fondazione Italiana Linfomi ONLUS

Terminated

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Diffuse Large B-Cell Lymphoma

Italy, China, Korea, Republic of, Canada, Australia, United States, Austria, Brazil, Denmark, Panama, Peru, Spain, Colombia, United Kingdom, Switzerland, Thailand, Mexico, Taiwan, Hong Kong, Russian Federation, Hungary, Japan, Germany, South Africa and more
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Non-GCB/ABC Diffuse Large B-Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

DLBCL | Untreated | MYC Gene Rearrangement

China
University of Birmingham
Acerta Pharma, LLC; Bloodwise

Recruiting

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome (STELLAR)

Richter Syndrome

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Lymphoma

United States, Brazil, Chile
National Cancer Institute (NCI)

Completed

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma

United States
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
National Cancer Institute (NCI)

Withdrawn

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Primary Effusion Lymphoma | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Xinjiang Medical University

Unknown

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Diffuse, Large B-Cell, Lymphoma

China
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Lymphoblastic Leukemia, Acute

United States
Hoffmann-La Roche
Norwegian Radium Hospital

Completed

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Breast Cancer

Norway
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development; Dutch...

Completed

Adjuvant HIPEC in High Risk Colon Cancer (COLOPEC)

Colorectal Neoplasms | Peritoneal Neoplasms

Netherlands
Universitätsklinikum Hamburg-Eppendorf

Completed

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Brain and Central Nervous System Tumors

Germany
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Lymphoma
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States

Search clinical trials for: Standard chemotherapy CHOP Ritiximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations